<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">AMB</journal-id><journal-title-group><journal-title>Advances in Microbiology</journal-title></journal-title-group><issn pub-type="epub">2327-0810</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/AMB.2021.101005</article-id><article-id pub-id-type="publisher-id">AMB-40900</article-id><article-categories><subj-group subj-group-type="heading"><subject>AMB20210100000_88552781.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>生命科学</subject></subj-group></article-categories><title-group><article-title>
 
 
  抗生素替代疗法：噬菌体疗法
  Antibiotic Replacement Therapy: Phage Therapy
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>向</surname><given-names>宇波</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>逸仙</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>艾</surname><given-names>沁悦</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>石</surname><given-names>廷玉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>湖北民族大学医学部病原生物学教研室，湖北 恩施</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>10</volume><issue>01</issue><fpage>30</fpage><lpage>42</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    近年来由于抗生素的滥用，细菌耐药已成为当前临床感染治疗面临的严峻问题，为解决细菌耐药的问题，科学家们再次把目光转移到被人们质疑甚至遗忘的噬菌体疗法上。噬菌体疗法通过噬菌体这种特殊的病毒及其衍生物可以裂解细菌治疗病原菌感染。噬菌体疗法在细菌耐药性日益严重的今天展现出了其独特的抗菌优势，是目前治疗细菌性感染特别是耐药菌的研究热点。本文对传统的常规噬菌体疗法以及以常规噬菌体疗法为基础演变而来的各种疗法进行了介绍，并分析了他们的优势和缺陷。
    In recent years, due to the abuse of antibiotics, bacterial resistance has become a serious problem in the treatment of clinical infection. In order to solve the problem of bacterial resistance, scientists once again turn their attention to the phage therapy which has been questioned or even forgotten by people. Phage therapy treats bacterial infections by using bacteria from this specific virus and its derivatives. Phage therapy has shown its unique antibacterial advantages in today’s increasingly serious bacterial resistance, and it is currently a research hotspot in the treatment of bacterial infections, especially drug-resistant bacteria. In this paper, we introduce the traditional conventional phage therapy and the various therapies that have evolved on the basis of conventional phage therapy, and analyze their advantages and disadvantages. 
  
 
</p></abstract><kwd-group><kwd>噬菌体，细菌耐药性，噬菌体疗法，裂解酶，基因工程, Phage</kwd><kwd> Bacterial Resistance</kwd><kwd> Phage Therapy</kwd><kwd> Lysase</kwd><kwd> Genetic Engineering</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>近年来由于抗生素的滥用，细菌耐药已成为当前临床感染治疗面临的严峻问题，为解决细菌耐药的问题，科学家们再次把目光转移到被人们质疑甚至遗忘的噬菌体疗法上。噬菌体疗法通过噬菌体这种特殊的病毒及其衍生物可以裂解细菌治疗病原菌感染。噬菌体疗法在细菌耐药性日益严重的今天展现出了其独特的抗菌优势，是目前治疗细菌性感染特别是耐药菌的研究热点。本文对传统的常规噬菌体疗法以及以常规噬菌体疗法为基础演变而来的各种疗法进行了介绍，并分析了他们的优势和缺陷。</p></sec><sec id="s2"><title>关键词</title><p>噬菌体，细菌耐药性，噬菌体疗法，裂解酶，基因工程</p></sec><sec id="s3"><title>Antibiotic Replacement Therapy: Phage Therapy</title><p>Yubo Xiang, Yixian Zhou, Qinyue Ai, Tingyu Shi<sup>*</sup></p><p>Department of Pathogenic Biology of Medical School, Hubei Minzu University, Enshi Hubei</p><p><img src="//html.hanspub.org/file/5-2730202x5_hanspub.png" /></p><p>Received: Feb. 11<sup>th</sup>, 2021; accepted: Mar. 1<sup>st</sup>, 2021; published: Mar. 12<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/5-2730202x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>In recent years, due to the abuse of antibiotics, bacterial resistance has become a serious problem in the treatment of clinical infection. In order to solve the problem of bacterial resistance, scientists once again turn their attention to the phage therapy which has been questioned or even forgotten by people. Phage therapy treats bacterial infections by using bacteria from this specific virus and its derivatives. Phage therapy has shown its unique antibacterial advantages in today’s increasingly serious bacterial resistance, and it is currently a research hotspot in the treatment of bacterial infections, especially drug-resistant bacteria. In this paper, we introduce the traditional conventional phage therapy and the various therapies that have evolved on the basis of conventional phage therapy, and analyze their advantages and disadvantages.</p><p>Keywords:Phage, Bacterial Resistance, Phage Therapy, Lysase, Genetic Engineering</p><disp-formula id="hanspub.40900-formula18"><graphic xlink:href="//html.hanspub.org/file/5-2730202x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/5-2730202x8_hanspub.png" /> <img src="//html.hanspub.org/file/5-2730202x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>所谓噬菌体疗法(phage therapy)就是利用噬菌体这种特殊的病毒治疗细菌所引起的各种感染。噬菌体是一种细菌病毒，它们无处不在，是生物圈中发现的最丰富的生物，是细菌在自然界中的天敌，它们是“细菌的捕食者”。早在上世纪初噬菌体被发现以来，人们就开始尝试利用它们天生的杀菌能力来治疗细菌感染 [<xref ref-type="bibr" rid="hanspub.40900-ref1">1</xref>]。噬菌体存在于所有生态系统中，包括人类身体的任何部位，它们是人体微生物群落中非常重要的成员，主要分布在口腔、胃肠道、阴道和皮肤等部位 [<xref ref-type="bibr" rid="hanspub.40900-ref2">2</xref>]。Mirzaei和他的同事们提出噬菌体和细菌以及人类肠道三分天下的新观念 [<xref ref-type="bibr" rid="hanspub.40900-ref3">3</xref>]。有研究表明，在动物和人类肠道的粘膜壁上有大量噬菌体稳定地附着，因此，它们可能构成一种“天然屏障”来防御潜在的有害细菌侵入肠，甚至进入到血液循环中 [<xref ref-type="bibr" rid="hanspub.40900-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.40900-ref5">5</xref>]。同时还发现噬菌体可以用来消除抗生素对人体胃肠道菌群的“普遍影响”所带来的严重后果 [<xref ref-type="bibr" rid="hanspub.40900-ref6">6</xref>]。噬菌体在新生儿胃肠道的微生物体系建立中也有不可替代的作用 [<xref ref-type="bibr" rid="hanspub.40900-ref7">7</xref>]。由此可以看出噬菌体对我们人类的身体健康有至关重要的作用。因此深入的认识和利用好噬菌体将有助于我们治疗和预防各种细菌感染。</p><p>事实上，噬菌体在被发现之初，科学家们利用噬菌体用来治疗细菌性感染。但是在当时那个年代，人们对噬菌体有关基础和临床研究很缺乏，对噬菌体的认识还不够深入甚至错误的把病毒视为“生命的敌人”等原因，导致人们对噬菌体疗法存在很多质疑 [<xref ref-type="bibr" rid="hanspub.40900-ref8">8</xref>]。再加上抗生素的出现也使得噬菌体治疗一度被搁置。然而，近年来由于细菌耐药性的日益严重以及越来越多具有抗生素抗性的“超级细菌”的出现，给临床治疗带来了巨大的挑战，人们又把眼光转移到饱受质疑甚至已经遗忘的噬菌体疗法上，希望它成为一种有效的治疗细菌感染的抗生素替代疗法 [<xref ref-type="bibr" rid="hanspub.40900-ref9">9</xref>]。因此这些年噬菌体的基础和临床研究得到了迅速的发展。噬菌体治疗细菌感染的方法也从传统的常规噬菌体疗法发展到用“工程噬菌体”、“噬菌体酶”(如裂解酶)以及联合使用噬菌体和抗生素等方法治疗各种感染 [<xref ref-type="bibr" rid="hanspub.40900-ref10">10</xref>]。</p><p>本文对传统的常规噬菌体疗法以及以常规噬菌体疗法为基础演变而来的各种疗法进行了综述并着重分析了他们的优势和缺陷，让我们更清楚的认识噬菌体疗法进而更好的利用各种与噬菌体相关治疗细菌感染的方法，为基础和临床研究提供新的思路，以促进噬菌体治疗细菌感染的发展。</p></sec><sec id="s6"><title>2. 常规噬菌体疗法</title><p>所谓传统的常规噬菌体治疗就是将从自然环境中分离出来的毒性噬菌体直接用于患者以溶解造成急慢性感染的病原体 [<xref ref-type="bibr" rid="hanspub.40900-ref10">10</xref>]。噬菌体根据其生长周期可以分为毒性噬菌体和溶原性噬菌体两种类型，用于治疗细菌感染的噬菌体大部分为毒性噬菌体。毒性噬菌体的生活周期一般包括吸附、穿入、脱壳、生物合成、成熟和释放等过程(图1) [<xref ref-type="bibr" rid="hanspub.40900-ref1">1</xref>]。噬菌体疗法就是使用毒性噬菌体裂解宿主菌以达到杀灭细菌的目的来治疗细菌感染。首先裂解噬菌体通过其尾丝与细菌胞壁受体特异性结合、再通过其尾髓的收缩向细菌内注射噬菌体的遗传物质、宿主菌提供复制噬菌体遗传物质和产生后代噬菌体所需要的成分和酶，当细胞内的噬菌体达到一定数量时，噬菌体会编码一些如穿孔素和裂解酶这样的蛋白，在这些蛋白共同作用下裂解宿主菌并迅速释放出大量的子代噬菌体到周围环境中，毒性噬菌体继续感染并摧毁邻近的细菌，如此循环来实现其抗菌作用 [<xref ref-type="bibr" rid="hanspub.40900-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.40900-ref12">12</xref>]。传统噬菌体疗法对比抗生素治疗细菌感染其优势有以下几点：</p><p>图1. 噬菌体的生命周期 [<xref ref-type="bibr" rid="hanspub.40900-ref1">1</xref>]。毒性噬菌体经历裂解周期，宿主菌被裂解，子代噬菌体被释放到环境中。溶原性噬菌体可经历溶菌或溶源周期，一些噬菌体依靠小分子交流来决定执行溶酶或溶源周期</p><sec id="s6_1"><title>2.1. 毒性噬菌体所具有的高度特异性是现有的抗生素无法比拟的</title><p>噬菌体仅仅感染其敏感菌株，而对非敏感菌株一般是不会感染的，因此噬菌体不会损害系统中的共生微生物，这是噬菌体治疗细菌感染最突出的优势 [<xref ref-type="bibr" rid="hanspub.40900-ref13">13</xref>]。再者，噬菌体不会感染真核细胞，因此理论上噬菌体完全可以用于治疗人类的细菌性感染 [<xref ref-type="bibr" rid="hanspub.40900-ref13">13</xref>]。而事实上，目前的研究也证实噬菌体疗法是安全的，其副作用也很小 [<xref ref-type="bibr" rid="hanspub.40900-ref14">14</xref>]。</p></sec><sec id="s6_2"><title>2.2. 噬菌体在非常恶劣的环境条件下仍然具有在其宿主细菌内进行繁殖的能力</title><p>噬菌体在非常恶劣的环境条件下仍然具有在其宿主细菌内进行繁殖的能力，倾向于继续复制，直到寄主细菌的种群密度显著降低。它们可通过一种“自动给药”的现象来确定剂量，这样就可避免在治疗部位重复多次使用噬菌体 [<xref ref-type="bibr" rid="hanspub.40900-ref15">15</xref>]。这些特性表明，与传统的抗生素治疗相比，噬菌体疗法可以需要更少或更有限的给药，从而减少了多次给药的麻烦，而治疗效果表现得更出色。</p></sec><sec id="s6_3"><title>2.3. 在缺少噬菌体所特有的细菌的情况下，噬菌体不会持续存在太长的时间</title><p>也就是说当宿主菌被裂解杀灭到一定程度后，噬菌体就会因为缺少宿主菌很快的自动清除 [<xref ref-type="bibr" rid="hanspub.40900-ref16">16</xref>]。因此噬菌体达到治疗目的后不会长期存在于人体中，从而可以避免外来噬菌体可能带来的相关副作用。</p></sec><sec id="s6_4"><title>2.4. 噬菌体感染和杀灭细菌的机理与抗生素不同，因此可用于治疗多重耐药细菌引起的感染</title><p>大部分噬菌体是利用由穿孔素(holin)和裂解酶(lysin)构成的穿孔素–裂解酶系统协同作用于细菌细胞壁并裂解细菌来杀死宿主细菌的 [<xref ref-type="bibr" rid="hanspub.40900-ref17">17</xref>]。穿孔素是一组噬菌体编码的膜蛋白，到目前为止一共发现有三类穿孔素，目前研究最广泛最深入的是属于I类穿孔素的大肠杆菌噬菌体λS105蛋白。宿主细胞的裂解由穿孔素触发，然后裂解酶通过由穿孔素在宿主细菌胞膜上形成的孔接触到细菌肽聚糖，破坏内肽酶、酰胺酶以及糖苷酶来水解细菌的肽聚糖使宿主细菌裂解，从而达到灭菌的效果 [<xref ref-type="bibr" rid="hanspub.40900-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.40900-ref19">19</xref>]。在噬菌体复制周期结束后子代病毒被释放出来去侵染周围的细菌。</p></sec><sec id="s6_5"><title>2.5. 噬菌体可单独或混合多种噬菌体使用以扩大其抗菌谱</title><p>噬菌体的高度特异性既是其优势也是其缺点，于是就出现了混合多种噬菌体等方法来改变或扩大噬菌体的宿主谱和裂解特性 [<xref ref-type="bibr" rid="hanspub.40900-ref20">20</xref>]。混合多种噬菌体治疗细菌感染除了扩大噬菌体的宿主谱和裂解特性外还能延缓细菌对噬菌体产生抗性和提高噬菌体疗效 [<xref ref-type="bibr" rid="hanspub.40900-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.40900-ref22">22</xref>]。</p></sec><sec id="s6_6"><title>2.6. 噬菌体在预防生物被膜的形成和清除已形成的生物被膜方面也具有抗生素无法 比拟的优势</title><p>细菌在一定条件下可以形成生物被膜，此时抗生素、免疫细胞和抗体对细菌的作用微乎其微，这样就容易导致慢性感染 [<xref ref-type="bibr" rid="hanspub.40900-ref23">23</xref>]。很多研究尝试用噬菌体来解决由生物被膜所引起的耐药问题。Hughes和其同事曾分离出可针对性降解肠细菌产生的粘多糖(EPS)的肠细菌噬菌体，该噬菌体能够破坏生物被膜并溶解细菌。相关研究发现，噬菌体在感染细菌后，会大量表达β-N-乙酰氨基葡萄糖苷酶(dispersin B, DspB)，其DspB酶可水解肺炎克雷伯菌等细菌生物被膜中关键交联基质1,6-N-乙酰-D-葡萄糖胺，从而破坏生物被膜并杀灭细菌，而且当抗生素与特定的噬菌体联合使用时，表现出对生物膜结构的更大破坏作用 [<xref ref-type="bibr" rid="hanspub.40900-ref24">24</xref>]。这种联合治疗表现出的另一个优势是可以阻止耐药突变体的形成，因为这些突变体在单独使用噬菌体或抗生素时很容易形成 [<xref ref-type="bibr" rid="hanspub.40900-ref25">25</xref>]。</p></sec><sec id="s6_7"><title>2.7. 噬菌体可以针对不断进化的细菌进行自我修正，以便继续感染和裂解细菌</title><p>宿主细菌为了在噬菌体的感染中存活下来，针对噬菌体吸附、穿入、生物合成、成熟和释放等过程，进化出各种机制来应对噬菌体的侵入、增殖和扩散。与之相对应，噬菌体也不断发展以对抗宿主细菌各种防御方式从而继续感染和裂解细菌。比如有一些噬菌体可以针对宿主菌的改变进化出一种被称作 “DGRs”的遗传元件，“DGRs”通过依赖模板的逆转录酶介导的作用，在噬菌体主要取向决定因素基因(major tropism determinant, mtd)中引入核苷酸置换，mtd基因编码的蛋白质的主要功能是对宿主菌进行识别，因此噬菌体也可以通过进化来改变甚至拓宽噬菌体的宿主谱以应对宿主菌的进化 [<xref ref-type="bibr" rid="hanspub.40900-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.40900-ref27">27</xref>]。另外，噬菌体还可以通过基因突变来对抗宿主细菌的反制措施，例如，噬菌体T4rII可以通过基因motA的突变来逃脱宿主菌Rex系统对其的清除 [<xref ref-type="bibr" rid="hanspub.40900-ref28">28</xref>]。与此类似，噬菌体同样可以通过基因突变来应对宿主菌的CRISPR-CAS系统和流产感染(Abi)系统。</p><p>经过多年的研究发现噬菌体治疗细菌感染还存在很多问题，正是这些问题和缺陷在阻碍噬菌体的应有。归纳总结出以下几点：</p></sec><sec id="s6_8"><title>2.8. 噬菌体的宿主谱窄</title><p>噬菌体通过其尾丝与细菌表面的受体相互识别，受体的特异性决定了大部分噬菌体只能够识别并感染特定种类的细菌 [<xref ref-type="bibr" rid="hanspub.40900-ref29">29</xref>]。因此在多病原菌感染的临床病例的情况下，传统的常规噬菌体疗法显然不能够满足需要。要解决这个尖锐的问题，可以通过筛选出同时具有广宿主谱和较强裂解能力的噬菌体。比如Yu和其同事通过连续多宿主分离噬菌体的方法，挑选出的噬菌体在裂解能力增强的同时还能裂解大肠埃希菌和铜绿假单胞菌 [<xref ref-type="bibr" rid="hanspub.40900-ref30">30</xref>]。另外一种增加噬菌体宿主谱的方法叫噬菌体鸡尾酒疗法。用噬菌体鸡尾酒疗法对多例链球菌感染受试者进行治疗，其效果明显提高 [<xref ref-type="bibr" rid="hanspub.40900-ref31">31</xref>]。此外，应用现代的生物信息学研究噬菌体基因组学也为筛选广谱噬菌体提供新思路。</p></sec><sec id="s6_9"><title>2.9. 存在抗噬菌体的宿主菌</title><p>噬菌体与细菌在亿万年的斗争中，彼此都进化出了许多相互防御约束的策略，宿主菌和噬菌体任何一方发生突变都会影响噬菌体对宿主菌的吸附率以及最终能否导致宿主菌的裂解。宿主细菌进化出了多种抗噬菌体的机制，包括修饰表面受体、超级感染排除(Sie)系统、限制修饰系统、规律成簇的间隔短回文重复(Clustered regularly interspaced short palindromic repeats, CRISPR)和流产感染(Abi)等机制(图2) [<xref ref-type="bibr" rid="hanspub.40900-ref32">32</xref>]。这些抗噬菌体的机制表现在抑制噬菌体的吸附、阻止噬菌体的遗传物质进入胞内、干扰甚至降解噬菌体遗传物质等，以应对噬菌体对宿主细菌的杀灭作用。</p><p>图2. 细菌对噬菌体的防御 [<xref ref-type="bibr" rid="hanspub.40900-ref32">32</xref>]。系统目前还没有发现一个细菌拥有所有这些防御系统，但是每个细菌可以有一个或者几个。粉红色的星代表基本的机制，包括DNA复制、转录、翻译、潜在的遗传和表型变异。红色的叉代表感染过程的停止。红色三角代表与流产感染(Abi)系统和超级感染排斥(Sie)机制相关。蓝色的DNA分子代表细菌的DNA。绿色的DNA分子代表噬菌体的DNA</p></sec><sec id="s6_10"><title>2.10. 机体的免疫系统对噬菌体颗粒具有灭活作用</title><p>有研究证实作为大分子颗粒的噬菌体具有抗原性，人体的先天免疫和适应性免疫都参与了噬菌体的清除。根据噬菌体的类型不同和给药途径的不同，对噬菌体的免疫反应也有所不同 [<xref ref-type="bibr" rid="hanspub.40900-ref33">33</xref>]。人类免疫系统可能会将噬菌体识别为外来抗原，并产生噬菌体中和抗体来做出反应 [<xref ref-type="bibr" rid="hanspub.40900-ref34">34</xref>]。另外，给患者注射高滴度的噬菌体可能会引起如过敏反应这样的强烈反应，如果反复给动物注射噬菌体可以导致血清中的抗体效价升高，尽管还没有观察到这种负面副作用 [<xref ref-type="bibr" rid="hanspub.40900-ref34">34</xref>]。不仅如此，由于噬菌体无法进入真核细胞，也就无法对已经进入细胞内的宿主细菌产生杀菌作用，从而细胞内的病原体具有在宿主细胞内存活的优势 [<xref ref-type="bibr" rid="hanspub.40900-ref34">34</xref>]。</p></sec><sec id="s6_11"><title>2.11. 噬菌体在体内的作用机制尚未研究清楚，有可能对机体造成我们尚不知道的危害</title><p>首先，常规噬菌体疗法裂解细菌会产生后续的影响，当革兰氏阴性菌被噬菌体裂解时，内毒素(Endotoxin)等细胞内成分就会被释放出来进入血液循环后引起发热、血压下降、休克、全身炎症综合征(Systemic Inflammatory Response Syndrome, SIRS)、多器官功能衰竭(Multiple Organ Dysfunction Syndrome, MODS)及播散性血管内凝血(DIC)等一系列疾病，严重威胁到患者的生命安全 [<xref ref-type="bibr" rid="hanspub.40900-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.40900-ref35">35</xref>] [<xref ref-type="bibr" rid="hanspub.40900-ref36">36</xref>]。Dufour和他的同事们 [<xref ref-type="bibr" rid="hanspub.40900-ref37">37</xref>] 提出可以通过比较暴露于噬菌体后细菌细胞裂解过程中内毒素(Endotoxin)释放的数据，来解决噬菌体治疗的临床安全性问题。其次，为防止机体的免疫系统在噬菌体尚未完成它的使命之前就把其清除，通过研究给药途径和方式来解决这一问题一直是研究噬菌体疗法的热点。由于胃部的酸性环境和胃肠道的蛋白酶的存在，因此选择口服噬菌体治疗细菌感染可能会导致噬菌体的失活 [<xref ref-type="bibr" rid="hanspub.40900-ref38">38</xref>]。Brown等人 [<xref ref-type="bibr" rid="hanspub.40900-ref39">39</xref>] 将处理痤疮丙酸杆菌的噬菌体制成乳膏，发现制成乳膏的噬菌体不仅可以长期保留噬菌体的活性和具有润肤的效果，而且还能使噬菌体与皮肤上的痤疮丙酸杆菌更加紧密接触。Bodier-Montagutelli对用吸入噬菌体的方式治疗呼吸道感染的相关问题进行了详细的描述 [<xref ref-type="bibr" rid="hanspub.40900-ref40">40</xref>]。另外，通过对噬菌体T7进行基因编辑，使其脂质能够与其衣壳结合，发现在不同条件下噬菌体的稳定性均得到提高 [<xref ref-type="bibr" rid="hanspub.40900-ref41">41</xref>]。静脉注射噬菌体还需要解决的一个主要问题是静脉注射的噬菌体溶液要与其他化学药物一样纯净。</p></sec><sec id="s6_12"><title>2.12. 噬菌体基因组可能会携带毒素和抗药性基因并且可以将这些特征赋予细菌</title><p>常见的大肠杆菌、化脓性链球菌等常见菌的毒素基因大部分都可以在对应的噬菌体基因组中发现。噬菌体可以通过溶源过程把噬菌体的毒素基因和耐药基因赋予细菌，这样一般菌株就可以转化为高致病性菌株，从而增强细菌的致病性导致急性和严重感染 [<xref ref-type="bibr" rid="hanspub.40900-ref42">42</xref>] [<xref ref-type="bibr" rid="hanspub.40900-ref43">43</xref>]。Keen和同事们报道了两个大肠埃希菌噬菌体可以通过溶源过程促进基因的转移，显著增加了抗生素抗性基因的传播 [<xref ref-type="bibr" rid="hanspub.40900-ref44">44</xref>]。经抗生素处理的噬菌体群体的基因组中抗生素抗性基因有聚集现象，这种抗生素抗性基因聚集现象在肺囊肿纤维化病人中 [<xref ref-type="bibr" rid="hanspub.40900-ref45">45</xref>] 和老鼠的粪便中都有发现 [<xref ref-type="bibr" rid="hanspub.40900-ref46">46</xref>]，因此在挑选噬菌体的时候，进行全基因的测序和分析是很有必要的。</p></sec></sec><sec id="s7"><title>3. 工程噬菌体</title><p>为了克服常规噬菌体疗法的一些缺陷，我们通过化学修饰或者利用基因工程等方法对噬菌体进行加工修饰，赋予噬菌体特殊的功能以克服常规噬菌体疗法的一些缺陷，再用于治疗细菌感染，在治疗中取得了显著效果。</p><sec id="s7_1"><title>3.1. 通过修饰噬菌体可以增加噬菌体在体内的循环时间</title><p>通过修饰噬菌体可以延迟机体对噬菌体的免疫反应为噬菌体的增殖赢得充分的时间，就会有更高数量的感染性噬菌体去感染细菌，从而增加了噬菌体治疗的功效。有文献描述将非免疫原性物质单甲氧基聚乙二醇(MPEG)附着到噬菌体表面(聚乙二醇化)增加了噬菌体在遇到该噬菌体的小鼠中的循环时间的同时还降低了辅助性T细胞1型免疫应答 [<xref ref-type="bibr" rid="hanspub.40900-ref47">47</xref>]。在λ Argo噬菌体衣壳蛋白中的单一氨基酸(158位谷氨酸残基转变为赖氨酸)取代可以导致噬菌体增加到长达1000倍的循环时间 [<xref ref-type="bibr" rid="hanspub.40900-ref48">48</xref>]。还有研究表明，脂质体包裹的噬菌体比使用常规噬菌体在治疗肺炎克雷伯菌所致小鼠肺部感染疗效更好，而且在减少炎性因子的同时还能增加抗炎性因子的作用 [<xref ref-type="bibr" rid="hanspub.40900-ref49">49</xref>]。</p></sec><sec id="s7_2"><title>3.2. 基因工程编辑噬菌体可以开发宿主范围更广的噬菌体</title><p>噬菌体的宿主谱窄是我们要面对的问题，利用基因工程技术编辑噬菌体后可以扩宽噬菌体的宿主谱。通过改变它们的尾部成分来改变其宿主范围 [<xref ref-type="bibr" rid="hanspub.40900-ref50">50</xref>]。比如，通过缺口修复克隆方法将重叠的、合成的噬菌体基因组片段以及合适的载体，转化到酵母中，通过重叠将片段连接在一起，并重建了基因组，由此产生的重组产物可以被提取出来，并“重新整合”到细菌宿主中，以生产带有操纵基因组的噬菌体，从而产生了能够感染新宿主的噬菌体，例如能够感染克雷伯氏菌的T7噬菌体 [<xref ref-type="bibr" rid="hanspub.40900-ref50">50</xref>]。我们还可以在T7Select噬菌体基因组中插入表达抗菌肽1018的编码序列，抗菌肽是一种有效的广谱抗菌生物膜剂，从而增加了噬菌体宿主谱 [<xref ref-type="bibr" rid="hanspub.40900-ref51">51</xref>]。同样的，长尾纤维基因的同源重组使噬菌体T2能够获得噬菌体IP008的更宽宿主范围，同时还能保持其自身的强裂解活性 [<xref ref-type="bibr" rid="hanspub.40900-ref52">52</xref>]。</p></sec><sec id="s7_3"><title>3.3. 利用基因工程编辑出的非裂解性噬菌体解决了噬菌体裂解细菌的过程中释放有毒物质的风险</title><p>通常，大噬菌体具有至少由一个穿孔素系统和一个裂解酶组成的双重裂解系统 [<xref ref-type="bibr" rid="hanspub.40900-ref53">53</xref>]。穿孔素会破坏胞膜，从而使裂解酶释放到肽聚糖中。紧随其后的是整个细胞被膜的解体，导致细胞壁成分的释放。通过构建裂解酶基因缺陷的噬菌体变异体，可以最大限度地减少或避免革兰氏阴性细菌释放内毒素。由于穿孔素功能导致膜电位的消散，不需要裂解酶裂解细菌也能杀死细菌，而且还具有保持其结构完整性的优点 [<xref ref-type="bibr" rid="hanspub.40900-ref54">54</xref>]。另一种避免细胞解体的策略是使用非裂解丝状噬菌体作为运送目标蛋白质的载体，例如将铜绿假单胞菌丝状噬菌体Pf3的转运蛋白基因替换为限制性内切酶基因。这使得Pf3变异体(Pf3R)不可复制而且阻止各种成分从靶细胞释放，从而在有效地杀死了野生型宿主细菌的同时还能大幅度的降低内毒素的释放 [<xref ref-type="bibr" rid="hanspub.40900-ref55">55</xref>]。</p></sec><sec id="s7_4"><title>3.4. 另一种有趣的方法是使用噬菌体将致死物质或基因定向的输送到感染部位</title><p>非裂解性的丝状噬菌体非常适合于此。把丝状噬菌体设计成能将编码毒性蛋白质的基因输送到目标细菌的载体，此方法在编码修饰Holin的吞噬致死基因 [<xref ref-type="bibr" rid="hanspub.40900-ref56">56</xref>]、限制性内切酶(可降解细菌基因组) [<xref ref-type="bibr" rid="hanspub.40900-ref57">57</xref>]、修饰的致死分解代谢基因激活蛋白(一种致死转录调节因子) [<xref ref-type="bibr" rid="hanspub.40900-ref58">58</xref>] 和成瘾毒素(可导致细胞程序性死亡)都获得了成功 [<xref ref-type="bibr" rid="hanspub.40900-ref59">59</xref>]。</p></sec><sec id="s7_5"><title>3.5. 噬菌体也可以作为抗生素的载体，抗生素可以被整合到噬菌体中或者附着在噬菌体表面</title><p>该策略的好处在于可以增加药物的特异性和感染部位的药物浓度。如将噬菌体纳米颗粒作为靶向、高容量的抗菌药物载体 [<xref ref-type="bibr" rid="hanspub.40900-ref60">60</xref>] [<xref ref-type="bibr" rid="hanspub.40900-ref61">61</xref>] 通过基因和化学修饰在其表面显示靶向部分(主要是抗体)，从而向目标细菌提供大量的细胞毒性药物。该平台是基于f1丝状聚合体，在小pIII被膜蛋白上显示抗菌肽或抗体。所展示的蛋白为病原菌提供了特异性的靶向性，细胞毒性药物(如氯霉素)经化学修饰后含有酯酶裂解敏感连接物，并通过亲水连接物(如氨基糖苷新霉素)与噬菌体发生化学结合。血清酯酶活性促进了药物释放的控制(或延迟)。在体外，靶向药物携带的噬菌体颗粒通过特异性识别几种模型致病菌并在目标细菌附近产生高的局部药物浓度和抑制其生长。与游离药物相比，以每个噬菌体含1万个氯霉素分子载体，其药效提高2万倍 [<xref ref-type="bibr" rid="hanspub.40900-ref62">62</xref>]。</p></sec></sec><sec id="s8"><title>4. 噬菌体酶，例如裂解酶</title><p>以DNA作为遗传物质的噬菌体在感染细菌的后期可以产生穿孔素和裂解酶。裂解酶穿过由穿孔素在细菌的胞膜上形成的孔道，到达作用靶点——肽聚糖，然后对组成肽聚糖的各种化学键进行水解，使细胞壁的完整性被破坏，宿主细菌发生崩解，子代噬菌体释到胞外。鉴于裂解酶具有崩解细菌的能力，我们可以跳过噬菌体的感染过程，直接利用裂解酶来杀灭细菌。革兰氏阴性菌有外膜结构阻挡裂解酶，因此裂解酶主要对革兰氏阳性菌发挥其裂解作用 [<xref ref-type="bibr" rid="hanspub.40900-ref63">63</xref>]。裂解酶的这些特征在治疗细菌感染可以解决传统噬菌体疗法在治疗细菌感染存在的问题，其优势有以下几点。</p><sec id="s8_1"><title>4.1. 裂解酶的抗菌作用具有“相对特异性”</title><p>裂解酶既没有噬菌体对宿主菌的高度特异性也没有抗生素的广谱性。例如，相对噬菌体而言裂解酶PlySs2 (来源于感染猪链球菌的噬菌体)对革兰氏阳性菌(包括MRSA、VISA、表皮葡萄球菌、化脓性链球菌、肺炎链球菌、血链球菌)表现出较宽的靶向，但是相对抗生素来说较窄的靶向 [<xref ref-type="bibr" rid="hanspub.40900-ref64">64</xref>]。</p></sec><sec id="s8_2"><title>4.2. 裂解酶的抗菌作用表现出“高效性”</title><p>由于噬菌体感染并杀死细菌需要经过复制周期，因此通常需要一定的时间。与之相比裂解酶的抗菌作用非常的高效，在与细菌接触的仅仅数秒就可以使细菌迅速裂解从而杀灭细菌，细菌的数量下降几个数量级也只需要很短的时间 [<xref ref-type="bibr" rid="hanspub.40900-ref65">65</xref>]。</p></sec><sec id="s8_3"><title>4.3. 裂解酶对破坏细菌形成的生物被膜同样有效</title><p>因为裂解酶抗菌作用的高效性，细菌在形成生物被膜之前就可能被清除，而且成熟生物被膜也可以被裂解酶破坏。Zhang Yufeng等人在研究中观察到溶解酶LysGH15不仅阻止了葡萄球菌形成生物被膜，而且还破坏了24小时和72小时的生物被膜。此外，LysGH15在小鼠表皮葡萄球菌菌血症模型中的体内疗效也得到了证实 [<xref ref-type="bibr" rid="hanspub.40900-ref66">66</xref>]。</p></sec><sec id="s8_4"><title>4.4. 裂解酶不易引起细菌对其产生抗性</title><p>由于裂解酶在胞壁上的受体为胆碱或者其它保守结构这些不容易被细菌改变的细胞壁成分。因此细菌很难产生针对裂解酶的抗性。到目前为止还没有观察到对内溶素的抗药性，这可能是噬菌体和细菌之间长期协同进化的结果 [<xref ref-type="bibr" rid="hanspub.40900-ref64">64</xref>] [<xref ref-type="bibr" rid="hanspub.40900-ref67">67</xref>] [<xref ref-type="bibr" rid="hanspub.40900-ref68">68</xref>]。</p></sec><sec id="s8_5"><title>4.5. 机体针对裂解酶产生的抗体并不会减弱其抗菌活性</title><p>这在很多研究中均有报道，裂解酶作为外源蛋白，机体对其很容易产生特异性抗体，但是这些抗体却不会显著影响裂解酶的杀菌活性。例如虽然裂解酶LysGH15在小鼠体内触发了特异性抗体的产生，但这些抗体在体外并没有破坏裂解活性(也没有阻断LysGH15的结合能力) [<xref ref-type="bibr" rid="hanspub.40900-ref69">69</xref>]。Mina Pastagia等人的实验测试了反复接触裂解酶ClyS后产生的抗体对ClyS杀伤能力的影响表明，在不同抗体效价下ClyS活性没有受到任何抑制 [<xref ref-type="bibr" rid="hanspub.40900-ref67">67</xref>]。</p></sec><sec id="s8_6"><title>4.6. 裂解酶之间以及与抗生素之间在抗菌方面具有协同作用</title><p>比如，肺炎球菌裂解酶Cpl-1与抗生素的联合使用就表现出这种协同作用，即使在降低青霉素MIC的情况下裂解酶Cpl-1和庆大霉素联合使用杀灭肺炎球菌的协同作用也有明显的效果，裂解酶Cpl-1和青霉素联合使用对一种极具青霉素耐药性的菌株也能表现出协同作用 [<xref ref-type="bibr" rid="hanspub.40900-ref70">70</xref>]。此外，Rashel等人在葡萄球菌特异性酶和糖肽类抗生素联合使用的过程中也观察到协同作用 [<xref ref-type="bibr" rid="hanspub.40900-ref71">71</xref>]。因此，酶和抗生素的正确组合不仅可以帮助控制抗药性细菌而且还可以恢复某些已经产生抗药性的抗生素的使用。</p></sec><sec id="s8_7"><title>4.7. 裂解酶容易进行自主改造</title><p>裂解酶本质是基因编码的蛋白质，通过蛋白质工程、结构域交换和基因重组都可以产生更好的裂解酶来控制各种环境中的细菌病原体 [<xref ref-type="bibr" rid="hanspub.40900-ref72">72</xref>]。通常裂解酶为模块式镶嵌结构，因此很容易对其进行改造，可以像搭积木一样对不同裂解酶的结合结构域和催化结构域进行拼搭，从中筛选更加优良的裂解酶改造体 [<xref ref-type="bibr" rid="hanspub.40900-ref73">73</xref>]。</p></sec></sec><sec id="s9"><title>5. 结论与展望</title><p>目前我们认识到的噬菌体与微生物群落和人体之间相互的作用只是冰山一角，采用宏基因组学和药理学研究噬菌体应该会有突破。对噬菌体的深入认识，将有助于我们利用噬菌体在诊断、治疗和预防感染方面起到重要作用。在细菌耐药性日益严重以及“超级细菌”出现的今天，噬菌体治疗细菌感染的进步让我们相信其非常有潜力成为抗生素的替代疗法。但是传统噬菌体疗法相对于目前的抗生素治疗细菌感染的优势非常有限。因此，人们又在传统噬菌体疗法的基础上进行改进，发展出了以噬菌体为基础的多种治疗细菌感染的方法。比如在基因工程技术突飞猛进的今天，利用基因工程技术根据具体需要改造出特定的噬菌体来治疗细菌感染正在日益增加。通过噬菌体将抗菌物质或基因定向的输送到感染部位来治疗感染也非常有潜力，尽管仍处于初级阶段。工程非裂解噬菌体具有内毒素释放少的优点的同时还排除了转基因噬菌体后代的传播。此外，随着分子生物学日新月异的发展，噬菌体编码表达的各种蛋白也在抗细菌感染中展现出巨大作用，特别是对革兰氏阳性细菌感染，噬菌体表达的裂解酶使用小剂量即可发挥强大的功能，机体针对裂解酶产生的抗体也不会削弱其抗菌活性，细菌不易对裂解酶产生抗性，并且消除了人们将噬菌体视为传统病毒的担心。同样，噬菌体和抗生素的联合使用治疗可以提高杀菌效果的同时耐药率还较低。</p><p>虽然噬菌体治疗细菌感染有如此多的优势，但仍然存在一些问题限制其广泛利用。首先是噬菌体及其衍生物的安全性问题，虽然目前还研究还没有发现存在严重的安全问题，但是仍然需要更多基础和临床研究来进一步证实其安全性。然后，细菌对噬菌体的耐药性以及机体对噬菌体的免疫作用，也是需要进一步深入研究的问题。在细菌与噬菌体共同进化的过程中，细菌进化出了修饰表面受体、超级感染排除系统、限制修饰系统、规律成簇的间隔短回文重复(CRISPR)和流产感染等一系列的机制来抗衡噬菌体的灭菌作用。机体的免疫系统也会针对噬菌体这种大分子颗粒做出反应。细菌与噬菌体的共同进化以及机体免疫系统对噬菌体反应直接影响噬菌体的抗菌效果。最后，人们普遍认为病毒都是对人体健康有害的，并不十分认可噬菌体还能用于临床治疗，从而在一定程度上限制其临床应用。因此未来我们可以把研究重点放在噬菌体疗法的安全性，噬菌体和细菌在斗争过程中的进化机制以及机体对噬菌体的免疫反应上来。从噬菌体、细菌和机体三个方向寻找出一些方法来确保噬菌体及其衍生物在临床应用过程中的安全，可以通过限制细菌进化出对噬菌体的防御机制以及降低机体对噬菌体免疫反应或者利用基因工程等技术增强噬菌体对细菌的侵染作用以及逃避机体的免疫系统的能力等来提高噬菌体的抗菌作用。为了改变人们认为病毒对人体健康都是有害的观念，促进人们对噬菌体治疗的接受程度，加强噬菌体常识的宣传也是必要的。除此以外，更广泛的使用噬菌体服务于临床，还需要国家出台相关制度支持和有相关机构监督以及药物制造厂商克服生产技术和规范管理等问题。</p><p>传统噬菌体疗法以及以传统噬菌体疗法为基础演变出来的各种治疗细菌感染的方法是极具潜力的治疗手段，为解决当前抗生素在治疗细菌感染遇到的问题开拓了一条崭新的道路。相信通过科学家们的潜心研究，我们能够解决目前噬菌体在基础研究和临床应用中遇到的重重困难，将噬菌体更好地应用于临床，服务于人类。</p></sec><sec id="s10"><title>基金项目</title><p>国家自然科学基金青年基金(批准号：81801979)、湖北民族大学国家级大学生创新创业训练计划(批准号：201910517004，201910517005)。</p></sec><sec id="s11"><title>文章引用</title><p>向宇波,周逸仙,艾沁悦,石廷玉. 抗生素替代疗法：噬菌体疗法Antibiotic Replacement Therapy: Phage Therapy[J]. 微生物前沿, 2021, 10(01): 30-42. https://doi.org/10.12677/AMB.2021.101005</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40900-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Doss, J., Culbertson, K., Hahn, D., Camacho, J. and Barekzi, N. (2017) A Review of Phage Therapy against Bacterial Pathogens of Aquatic and Terrestrial Organisms. Viruses Basel, 9, E50. &lt;br&gt;https://doi.org/10.3390/v9030050</mixed-citation></ref><ref id="hanspub.40900-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Wahida, A., Ritter, K. and Horz, H.P. (2016) The Janus-Face of Bacteriophages across Human Body Habitats. PLOS Pathogens, 12, e1005634. &lt;br&gt;https://doi.org/10.1371/journal.ppat.1005634</mixed-citation></ref><ref id="hanspub.40900-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Mirzaei, M.K. and Maurice, C.F. (2017) Menage a Trois in the Human Gut: Interactions between Host, Bacteria and Phages. Nature Reviews Microbiology, 15, 397-408. &lt;br&gt;https://doi.org/10.1038/nrmicro.2017.30</mixed-citation></ref><ref id="hanspub.40900-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Barr, J.J., et al. (2013) Bacteriophage Adhering to Mucus Provide a Non-Host-Derived Immunity. Proceedings of the National Academy of Sciences of the United States of America, 110, 10771-10776.  
&lt;br&gt;https://doi.org/10.1073/pnas.1305923110</mixed-citation></ref><ref id="hanspub.40900-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Duerkop, B.A. and Hooper, L.V. (2013) Resident Viruses and Their Interactions with the Immune System. Nature Immunology, 14, 654-659. &lt;br&gt;https://doi.org/10.1038/ni.2614</mixed-citation></ref><ref id="hanspub.40900-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Huse, S.M., et al. (2008) Exploring Microbial Diversity and Taxonomy Using SSU rRNA Hypervariable Tag Sequencing. PLOS Genetics, 4, e1000255. &lt;br&gt;https://doi.org/10.1371/journal.pgen.1000255</mixed-citation></ref><ref id="hanspub.40900-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Barr, J.J., Youle, M. and Rohwer, F. (2013) Innate and Acquired Bacteriophage-Mediated Immunity. Bacteriophage, 3, e25857. &lt;br&gt;https://doi.org/10.4161/bact.25857</mixed-citation></ref><ref id="hanspub.40900-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Verbeken, G., et al. (2007) European Regulatory Conundrum of Phage Therapy. Future Microbiology, 2, 485-491.  
&lt;br&gt;https://doi.org/10.2217/17460913.2.5.485</mixed-citation></ref><ref id="hanspub.40900-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Shigenobu, M., et al. (2005) Bacteriophage Therapy: A Revitalized Therapy against Bacterial Infectious Diseases. Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy, 11, 211-219.  
&lt;br&gt;https://doi.org/10.1007/s10156-005-0408-9</mixed-citation></ref><ref id="hanspub.40900-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Viertel, T.M., Ritter, K. and Horz, H.P. (2014) Viruses versus Bacteria-Novel Approaches to Phage Therapy as a Tool against Multidrug-Resistant Pathogens. Journal of Antimicrobial Chemotherapy, 69, 2326-2336.  
&lt;br&gt;https://doi.org/10.1093/jac/dku173</mixed-citation></ref><ref id="hanspub.40900-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">O’Flaherty, S., Ross, R.P. and Coffey, A. (2009) Bacteriophage and Their Lysins for Elimination of Infectious Bacteria. FEMS Microbiology Reviews, 33, 801-819. &lt;br&gt;https://doi.org/10.1111/j.1574-6976.2009.00176.x</mixed-citation></ref><ref id="hanspub.40900-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Wittebole, X., De Roock, S. and Opal, S.M. (2014) A Historical Overview of Bacteriophage Therapy as an Alternative to Antibiotics for the Treatment of Bacterial Pathogens. Virulence, 5, 226-235. &lt;br&gt;https://doi.org/10.4161/viru.25991</mixed-citation></ref><ref id="hanspub.40900-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Sylwia, P., Magdalena, K., Romuald, G., Lidia, M. and Anna, M. (2014) Bacteriophages as an Alternative Strategy for Fighting Biofilm Development. Polish Journal of Microbiology, 63, 137-145. &lt;br&gt;https://doi.org/10.33073/pjm-2014-019</mixed-citation></ref><ref id="hanspub.40900-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Ul, H.I., Nasir, C.W., Nadeem, A.M., Saadia, A. and Ishtiaq, Q. (2012) Bacteriophages and Their Implications on Future Biotechnology: A Review. Virology Journal, 9, 9.</mixed-citation></ref><ref id="hanspub.40900-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Schmelcher, M. and Loessner, M.J. (2014) Application of Bacteriophages for Detection of Foodborne Pathogens. Bacteriophage, 4, e28137. &lt;br&gt;https://doi.org/10.4161/bact.28137</mixed-citation></ref><ref id="hanspub.40900-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Clark, J.R. and March, J.B. (2006) Bacteriophages and Biotechnology: Vaccines, Gene Therapy and Antibacterials. Trends in Biotechnology, 24, 212-218. &lt;br&gt;https://doi.org/10.1016/j.tibtech.2006.03.003</mixed-citation></ref><ref id="hanspub.40900-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Shi, Y.B., et al. (2012) Characterization and Determination of Holin Protein of Streptococcus suis Bacteriophage SMP in Heterologous Host. Virology Journal, 9, Article No. 70. &lt;br&gt;https://doi.org/10.1186/1743-422X-9-70</mixed-citation></ref><ref id="hanspub.40900-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Wang, I.N., Smith, D.L. and Young, R. (2000) Holins: The Protein Clocks of Bacteriophage Infections. Annual Review of Microbiology, 54, 799-825. &lt;br&gt;https://doi.org/10.1146/annurev.micro.54.1.799</mixed-citation></ref><ref id="hanspub.40900-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Linden, S.B., et al. (2015) Biochemical and Biophysical Characterization of PlyGRCS, a Bacteriophage Endolysin Active against Methicillin-Resistant Staphylococcus aureus. Applied Microbiology and Biotechnology, 99, 741-752.  
&lt;br&gt;https://doi.org/10.1007/s00253-014-5930-1</mixed-citation></ref><ref id="hanspub.40900-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Mapes, A.C., Trautner, B.W., Liao, K.S. and Bacteriophage, R.F.R.J. (2016) Development of Expanded Host Range Phage Active on Biofilms of Multi-Drug Resistant Pseudomonas aeruginosa. Bacteriophage, 6, e1096995.  
&lt;br&gt;https://doi.org/10.1080/21597081.2015.1096995</mixed-citation></ref><ref id="hanspub.40900-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Hendrix, R.W., Smith, M.C.M., Burns, R.N., Ford, M.E. and Hatfull, G.F. (1999) Evolutionary Relationships among Diverse Bacteriophages and Prophages: All the World’s a Phage. Proceedings of the National Academy of Sciences of the United States of America, 96, 2192-2197. &lt;br&gt;https://doi.org/10.1073/pnas.96.5.2192</mixed-citation></ref><ref id="hanspub.40900-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Chibani-Chennoufi, S., Bruttin, A., Dillmann, M.L. and Brussow, H. (2004) Phage-Host Interaction: An Ecological Perspective. Journal of Bacteriology, 186, 3677-3686. &lt;br&gt;https://doi.org/10.1128/JB.186.12.3677-3686.2004</mixed-citation></ref><ref id="hanspub.40900-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Yang, W., et al. (2016) Isolation, Phylogenetic Group, Drug Resistance, Biofilm Formation, and Adherence Genes of Escherichia coli from Poultry in Central China. Poultry Science, 95, 2895-2901. &lt;br&gt;https://doi.org/10.3382/ps/pew252</mixed-citation></ref><ref id="hanspub.40900-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Verma, V., Harjai, K. and Chhibber, S. (2010) Structural Changes Induced by a Lytic Bacteriophage Make Ciprofloxacin Effective against Older Biofilm of Klebsiella pneumoniae. Biofouling, 26, 729-737.  
&lt;br&gt;https://doi.org/10.1080/08927014.2010.511196</mixed-citation></ref><ref id="hanspub.40900-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Bedi, M.S., Verma, V. and Chhibber, S. (2009) Amoxicillin and Specific Bacteriophage Can Be Used Together for Eradication of Biofilm of Klebsiella pneumoniae B5055. World Journal of Microbiology and Biotechnology, 25, 1145-1151. &lt;br&gt;https://doi.org/10.1007/s11274-009-9991-8</mixed-citation></ref><ref id="hanspub.40900-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Liu, M.S., et al. (2002) Reverse Transcriptase-Mediated Tropism Switching in Bordetella bacteriophage. Science, 295, 2091-2094. &lt;br&gt;https://doi.org/10.1126/science.1067467</mixed-citation></ref><ref id="hanspub.40900-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Yen, L., et al. (2004) Exogenous Control of Mammalian Gene Expression through Modulation of RNA Self-Cleavage. Nature, 431, 471-476. &lt;br&gt;https://doi.org/10.1038/nature02844</mixed-citation></ref><ref id="hanspub.40900-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Shinedling, S., et al. (1987) Wild-Type Bacteriophage T4 Is Restricted by the Lambda Rex Genes. Journal of Virology, 61, 3790-3794. &lt;br&gt;https://doi.org/10.1128/JVI.61.12.3790-3794.1987</mixed-citation></ref><ref id="hanspub.40900-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Drulis-Kawa, Z., Majkowska-Skrobek, G. and Maciejewska, B. (2015) Bacteriophages and Phage-Derived Proteins—Application Approaches. Current Medicinal Chemistry, 22, 1757-1773.  
&lt;br&gt;https://doi.org/10.2174/0929867322666150209152851</mixed-citation></ref><ref id="hanspub.40900-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Yu, P., Mathieu, J., Li, M., Dai, Z. and Alvarez, P.J. (2016) Isolation of Polyvalent Bacteriophages by Sequential Multiple-Host Approaches. Applied and Environmental Microbiology, 82, 808-815. &lt;br&gt;https://doi.org/10.1128/AEM.02382-15</mixed-citation></ref><ref id="hanspub.40900-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Zaczek, M., et al. (2016) Antibody Production in Response to Staphylococcal MS-1 Phage Cocktail in Patients Undergoing Phage Therapy. Frontiers in Microbiology, 7, 1681. &lt;br&gt;https://doi.org/10.3389/fmicb.2016.01681</mixed-citation></ref><ref id="hanspub.40900-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Merabishvili, M., et al. (2009) Quality-Controlled Small-Scale Production of a Well-Defined Bacteriophage Cocktail for Use in Human Clinical Trials. PLoS ONE, 4, e4944. &lt;br&gt;https://doi.org/10.1371/journal.pone.0004944</mixed-citation></ref><ref id="hanspub.40900-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Cisek, A.A., Dabrowska, I., Gregorczyk, K.P. and Wyzewski, Z. (2017) Phage Therapy in Bacterial Infections Treatment: One Hundred Years after the Discovery of Bacteriophages. Current Microbiology, 74, 277-283.  
&lt;br&gt;https://doi.org/10.1007/s00284-016-1166-x</mixed-citation></ref><ref id="hanspub.40900-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Sulakvelidze, A., et al. (2001) Bacteriophage Therapy. Antimicrobial Agents and Chemotherapy, 45, 649-659.  
&lt;br&gt;https://doi.org/10.1128/AAC.45.3.649-659.2001</mixed-citation></ref><ref id="hanspub.40900-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Plociennikowska, A., Hromada-Judycka, A., Borzecka, K. and Kwiatkowska, K. (2015) Co-Operation of TLR4 and Raft Proteins in LPS-Induced Pro-Inflammatory Signaling. Cellular and Molecular Life Sciences, 72, 557-581.  
&lt;br&gt;https://doi.org/10.1007/s00018-014-1762-5</mixed-citation></ref><ref id="hanspub.40900-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Lepper, P.M., et al. (2002) Clinical Implications of Antibiotic-Induced Endotoxin Release in Septic Shock. Intensive Care Medicine, 28, 824-833. &lt;br&gt;https://doi.org/10.1007/s00134-002-1330-6</mixed-citation></ref><ref id="hanspub.40900-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Dufour, N., Delattre, R., Ricard, J.D. and Debarbieux, L. (2017) The Lysis of Pathogenic Escherichia coli by Bacteriophages Releases Less Endotoxin Than by Beta-Lactams. Clinical Infectious Diseases, 64, 1582-1588.  
&lt;br&gt;https://doi.org/10.1093/cid/cix184</mixed-citation></ref><ref id="hanspub.40900-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Zelasko, S., Gorski, A. and Dabrowska, K. (2017) Delivering Phage Therapy per os: Benefits and Barriers. Expert Review of Anti-Infective Therapy, 15, 167-179. &lt;br&gt;https://doi.org/10.1080/14787210.2017.1265447</mixed-citation></ref><ref id="hanspub.40900-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Brown, T.L., Petrovski, S., Dyson, Z.A., Seviour, R. and Tucci, J. (2016) The Formulation of Bacteriophage in a Semi Solid Preparation for Control of Propionibacterium acnes Growth. PLoS ONE, 11, e0151184.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0151184</mixed-citation></ref><ref id="hanspub.40900-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Bodier-Montagutelli, E., et al. (2017) Inhaled Phage Therapy: A Promising and Challenging Approach to Treat Bacterial Respiratory Infections. Expert Opinion on Drug Delivery, 14, 959-972.  
&lt;br&gt;https://doi.org/10.1080/17425247.2017.1252329</mixed-citation></ref><ref id="hanspub.40900-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Ooi, M.L., et al. (2019) Safety and Tolerability of Bacteriophage Therapy for Chronic Rhinosinusitis Due to Staphylococcus aureus. JAMA Otolaryngology—Head and Neck Surgery, 145, 723-729.  
&lt;br&gt;https://doi.org/10.1001/jamaoto.2019.1191</mixed-citation></ref><ref id="hanspub.40900-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Nobrega, F.L., Costa, A.R., Kluskens, L.D. and Azeredo, J. (2015) Revisiting Phage Therapy: New Applications for Old Resources. Trends in Microbiology, 23, 185-191. &lt;br&gt;https://doi.org/10.1016/j.tim.2015.01.006</mixed-citation></ref><ref id="hanspub.40900-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Chan, B.K., et al. (2013) Phage Cocktails and the Future of Phage Therapy. Future Microbiology, 8, 769-783.  
&lt;br&gt;https://doi.org/10.2217/fmb.13.47</mixed-citation></ref><ref id="hanspub.40900-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Keen, E.C., et al. (2017) Novel “Superspreader” Bacteriophages Promote Horizontal Gene Transfer by Transformation. mBio, 8, e02115-16. &lt;br&gt;https://doi.org/10.1128/mBio.02115-16</mixed-citation></ref><ref id="hanspub.40900-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Fancello, L., Desnues, C., Raoult, D. and Rolain, J.M. (2011) Bacteriophages and Diffusion of Genes Encoding Antimicrobial Resistance in Cystic Fibrosis Sputum Microbiota. Journal of Antimicrobial Chemotherapy, 66, 2448-2454.  
&lt;br&gt;https://doi.org/10.1093/jac/dkr315</mixed-citation></ref><ref id="hanspub.40900-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Modi, S.R., Lee, H.H., Spina, C.S. and Collins, J.J. (2013) Antibiotic Treatment Expands the Resistance Reservoir and Ecological Network of the Phage Metagenome. Nature, 499, 219-222. &lt;br&gt;https://doi.org/10.1038/nature12212</mixed-citation></ref><ref id="hanspub.40900-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Kim, K.P., et al. (2008) PEGylation of Bacteriophages Increases Blood Circulation Time and Reduces T-Helper Type 1 Immune Response. Microbial Biotechnology, 1, 247-257. &lt;br&gt;https://doi.org/10.1111/j.1751-7915.2008.00028.x</mixed-citation></ref><ref id="hanspub.40900-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Vitiello, C.L., Merril, C.R. and Adhya, S. (2005) An Amino Acid Substitution in a Capsid Protein Enhances Phage Survival in Mouse Circulatory System More than a 1000-Fold. Virus Research, 114, 101-103.  
&lt;br&gt;https://doi.org/10.1016/j.virusres.2005.05.014</mixed-citation></ref><ref id="hanspub.40900-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Singla, S.i, Harjai, K., Katare, O.P. and Chhibber, S. (2015) Bacteriophage-Loaded Nanostructured Lipid Carrier: Improved Pharmacokinetics Mediates Effective Resolution of Klebsiella pneumoniae-Induced Lobar Pneumonia. The Journal of Infectious Diseases, 212, 325-334.</mixed-citation></ref><ref id="hanspub.40900-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Ando, H., Lemire, S., Pires, D.P. and Lu, T.K. (2015) Engineering Modular Viral Scaffolds for Targeted Bacterial Population Editing. Cell Systems, 1, 187-196. &lt;br&gt;https://doi.org/10.1016/j.cels.2015.08.013</mixed-citation></ref><ref id="hanspub.40900-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Lemon, D.J., et al. (2019) Construction of a Genetically Modified T7Select Phage System to Express the Antimicrobial Peptide 1018. Journal of Microbiology, 57, 532-538. &lt;br&gt;https://doi.org/10.1007/s12275-019-8686-6</mixed-citation></ref><ref id="hanspub.40900-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Faezeh, M., John, S.A., Keiko, Y., Toshiya, O. and Yasunori, T. (2009) Site-Specific Recombination of T2 Phage Using IP008 Long Tail Fiber Genes Provides a Targeted Method for Expanding Host Range While Retaining Lytic Activity. FEMS Microbiology Letters, 295, 211-217. &lt;br&gt;https://doi.org/10.1111/j.1574-6968.2009.01588.x</mixed-citation></ref><ref id="hanspub.40900-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Young, R. and Bläsi, U. (1995) Holins: Form and Function in Bacteriophage Lysis. FEMS Microbiology Reviews, 17, 191-205. &lt;br&gt;https://doi.org/10.1111/j.1574-6976.1995.tb00202.x</mixed-citation></ref><ref id="hanspub.40900-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">Rietsch, A. and Bläsi, U. (1993) Non-Specific Hole Formation in the Escherichia coli Inner Membrane by Lambda S Proteins in Independent of Cellular secY and secA Functions and of the Proportion of Membrane Acidic Phospholipids. FEMS Microbiology Letters, 107, 101-105. &lt;br&gt;https://doi.org/10.1016/0378-1097(93)90361-5</mixed-citation></ref><ref id="hanspub.40900-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Hagens, S., Habel, A., von Ahsen, U., von Gabain, A. and Blasi, U. (2004) Therapy of Experimental Pseudomonas Infections with a Nonreplicating Genetically Modified Phage. Antimicrobial Agents and Chemotherapy, 48, 3817-3822.  
&lt;br&gt;https://doi.org/10.1128/AAC.48.10.3817-3822.2004</mixed-citation></ref><ref id="hanspub.40900-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">Hagens, S. and Blasi, U. (2003) Genetically Modified Filamentous Phage as Bactericidal Agents: A Pilot Study. Letters in Applied Microbiology, 37, 318-323. &lt;br&gt;https://doi.org/10.1046/j.1472-765X.2003.01400.x</mixed-citation></ref><ref id="hanspub.40900-ref57"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">Steven, H., Andrę, H., Uwe, V.A., Alexander, V.G. and Udo, B.Ą. (2004) Therapy of Experimental Pseudomonas Infections with a Nonreplicating Genetically Modified Phage. Antimicrobial Agents and Chemotherapy, 48, 3817-3822.  
&lt;br&gt;https://doi.org/10.1128/AAC.48.10.3817-3822.2004</mixed-citation></ref><ref id="hanspub.40900-ref58"><label>58</label><mixed-citation publication-type="other" xlink:type="simple">Moradpour, Z., et al. (2009) Genetically Engineered Phage Harbouring the Lethal Catabolite Gene Activator Protein Gene with an Inducer-Independent Promoter for Biocontrol of Escherichia coli. FEMS Microbiology Letters, 296, 67-71. &lt;br&gt;https://doi.org/10.1111/j.1574-6968.2009.01620.x</mixed-citation></ref><ref id="hanspub.40900-ref59"><label>59</label><mixed-citation publication-type="other" xlink:type="simple">Westwater, C., et al. (2003) Use of Genetically Engineered Phage to Deliver Antimicrobial Agents to Bacteria: An Alternative Therapy for Treatment of Bacterial Infections. Antimicrobial Agents and Chemotherapy, 47, 1301-1307.  
&lt;br&gt;https://doi.org/10.1128/AAC.47.4.1301-1307.2003</mixed-citation></ref><ref id="hanspub.40900-ref60"><label>60</label><mixed-citation publication-type="other" xlink:type="simple">Iftach, Y., Marina, S., Hagit, B., Doron, S. and Itai, B. (2006) Targeting Antibacterial Agents by Using Drug-Carrying Filamentous Bacteriophages. Antimicrobial Agents and Chemotherapy, 50, 2087-2097.  
&lt;br&gt;https://doi.org/10.1128/AAC.00169-06</mixed-citation></ref><ref id="hanspub.40900-ref61"><label>61</label><mixed-citation publication-type="other" xlink:type="simple">Yacoby, I., Bar, H. and Benhar, I. (2007) Targeted Drug-Carrying Bacteriophages as Antibacterial Nanomedicines. Antimicrobial Agents and Chemotherapy, 51, 2156-2163. &lt;br&gt;https://doi.org/10.1128/AAC.00163-07</mixed-citation></ref><ref id="hanspub.40900-ref62"><label>62</label><mixed-citation publication-type="other" xlink:type="simple">Vaks, L. and Benhar, I. (2011) In Vivo Characteristics of Targeted Drug-Carrying Filamentous Bacteriophage Nanomedicines. Journal of Nanobiotechnology, 9, Article No. 58. &lt;br&gt;https://doi.org/10.1186/1477-3155-9-58</mixed-citation></ref><ref id="hanspub.40900-ref63"><label>63</label><mixed-citation publication-type="other" xlink:type="simple">Fischetti, V.A. (2005) Bacteriophage Lytic Enzymes: Novel Anti-Infectives. Trends in Microbiology, 13, 491-496.  
&lt;br&gt;https://doi.org/10.1016/j.tim.2005.08.007</mixed-citation></ref><ref id="hanspub.40900-ref64"><label>64</label><mixed-citation publication-type="other" xlink:type="simple">Gilmer, D.B., Schmitz, J.E., Euler, C.W. and Fischetti, V.A. (2013) Novel Bacteriophage Lysin with Broad Lytic Activity Protects against Mixed Infection by Streptococcus pyogenes and Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 57, 2743-2750. &lt;br&gt;https://doi.org/10.1128/AAC.02526-12</mixed-citation></ref><ref id="hanspub.40900-ref65"><label>65</label><mixed-citation publication-type="other" xlink:type="simple">Feifei, X., et al. (2016) Combination Therapy of LysGH15 and Apigenin as a New Strategy for Treating Pneumonia Caused by Staphylococcus aureus. Applied and Environmental Microbiology, 82, 87-94.  
&lt;br&gt;https://doi.org/10.1128/AEM.02581-15</mixed-citation></ref><ref id="hanspub.40900-ref66"><label>66</label><mixed-citation publication-type="other" xlink:type="simple">Yufeng, Z., et al. (2018) Antibacterial Effects of Phage Lysin LysGH15 on Planktonic Cells and Biofilms of Diverse Staphylococci. Applied and Environmental Microbiology, 84, e00886-18. &lt;br&gt;https://doi.org/10.1128/AEM.00886-18</mixed-citation></ref><ref id="hanspub.40900-ref67"><label>67</label><mixed-citation publication-type="other" xlink:type="simple">Pastagia, M., et al. (2011) A Novel Chimeric Lysin Shows Superiority to Mupirocin for Skin Decolonization of Methicillin-Resistant and -Sensitive Staphylococcus aureus Strains. Antimicrobial Agents and Chemotherapy, 55, 738-744.  
&lt;br&gt;https://doi.org/10.1128/AAC.00890-10</mixed-citation></ref><ref id="hanspub.40900-ref68"><label>68</label><mixed-citation publication-type="other" xlink:type="simple">Rodr├şguez-Rubio, L., et al. (2018) The Phage Lytic Proteins from the Staphylococcus aureus Bacteriophage vB_SauS-phiIPLA88 Display Multiple Active Catalytic Domains and Do Not Trigger Staphylococcal Resistance. PLoS ONE, 8, e64671. &lt;br&gt;https://doi.org/10.1371/journal.pone.0064671</mixed-citation></ref><ref id="hanspub.40900-ref69"><label>69</label><mixed-citation publication-type="other" xlink:type="simple">Lei, Z., et al. (2016) LysGH15 Kills Staphylococcus aureus without Being Affected by the Humoral Immune Response or Inducing Inflammation. Scientific Reports, 6, Article No. 29344. &lt;br&gt;https://doi.org/10.1038/srep29344</mixed-citation></ref><ref id="hanspub.40900-ref70"><label>70</label><mixed-citation publication-type="other" xlink:type="simple">Svetolik, D., et al. (2005) Synergistic Killing of Streptococcus pneumoniae with the Bacteriophage Lytic Enzyme Cpl-1 and Penicillin or Gentamicin Depends on the Level of Penicillin Resistance. Antimicrobial Agents and Chemotherapy, 49, 1225-1228. &lt;br&gt;https://doi.org/10.1128/AAC.49.3.1225-1228.2005</mixed-citation></ref><ref id="hanspub.40900-ref71"><label>71</label><mixed-citation publication-type="other" xlink:type="simple">Mohammad, R., et al. (2007) Efficient Elimination of Multidrug-Resistant Staphylococcus aureus by Cloned Lysin Derived from Bacteriophage Phi MR11. The Journal of Infectious Diseases, 196, 1237-1247.  
&lt;br&gt;https://doi.org/10.1086/521305</mixed-citation></ref><ref id="hanspub.40900-ref72"><label>72</label><mixed-citation publication-type="other" xlink:type="simple">Fischetti, V.A. (2010) Bacteriophage Endolysins: A Novel Anti-Infective to Control Gram-Positive Pathogens. International Journal of Medical Microbiology, 300, 357-362. &lt;br&gt;https://doi.org/10.1016/j.ijmm.2010.04.002</mixed-citation></ref><ref id="hanspub.40900-ref73"><label>73</label><mixed-citation publication-type="other" xlink:type="simple">Jingmin, G., et al. (2014) Structural and Biochemical Characterization Reveals LysGH15 as an Unprecedented “EF-Hand-Like” Calcium-Binding Phage Lysin. PLoS Pathogens, 10, e1004109.  
&lt;br&gt;https://doi.org/10.1371/journal.ppat.1004109</mixed-citation></ref></ref-list></back></article>